Abstract
Disclosed herein are methods of producing glyco-modified viral antigens that provide a shift of the glycosylation profile of recombinant produced viral antigens (e.g. glycoproteins) towards the naturally occurring viral antigens (e.g. glycoproteins). Disclosed are methods of producing a modified viral antigen comprising expressing a viral antigen in a recombinant mammalian cell line having one or more of the endogenous genes Mgat2, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, B4galtl, B4galt2, B4galt3, B4galt4, B4galt5, B3gnt2, St3Gal6, SPPL3, and/or FUT8 inactivated and/or downregulated; and optionally a gene ST6Gall inserted. Disclosed are glyco-modified viral antigens produced by the method of using a recombinant mammalian cell line. Disclosed are methods of treating a subject in need thereof comprising administering a composition comprising a therapeutically effective amount of one or more of the glyco-modified viral antigens. Disclosed are methods of screening for an antibody specific to one or more of the disclosed glyco-modified viral antigens.
| Original language | English |
|---|---|
| IPC | A61K 39/ 29 A I |
| Patent number | WO2022165194 |
| Filing date | 29/01/2021 |
| Country/Territory | International Bureau of the World Intellectual Property Organization (WIPO) |
| Priority date | 29/01/2021 |
| Priority number | US202163143410P |
| Publication status | Published - 4 Aug 2022 |